• IDEXX Laboratories recently prepared to release its fiscal Q4 2025 results, with analysts highlighting ongoing profit strength supported by its Companion Animal Group Diagnostics segment and growing demand for diagnostic instruments and cloud-based software.
• Analysts’ consistently optimistic earnings expectations and the company’s track record of surpassing profit estimates have reinforced confidence in the resilience of IDEXX’s diagnostics-led business model.
• Now, we’ll examine how optimism around stronger Companion Animal Group Diagnostics earnings might influence IDEXX Laboratories’ existing investment narrative.

Rare earth metals are an input to most high-tech devices, military and defence systems and electric vehicles. The global race is on to secure supply of these critical minerals. Beat the pack to uncover the 39 best rare earth metal stocks of the very few that mine this essential strategic resource.

IDEXX Laboratories Investment Narrative Recap

To own IDEXX, you need to believe that diagnostic testing and software will remain central to companion animal care, supporting recurring, high margin revenue from its installed base. The latest expectations for another quarter of solid Companion Animal Group Diagnostics profits appear to support this near term earnings catalyst, while the biggest risk still looks to be any sustained softness in veterinary visit volumes that would eventually test the strength of that recurring demand.

Among recent announcements, IDEXX’s raised 2025 revenue and EPS guidance stands out in this context, as it reflects management’s confidence in continued momentum from diagnostics and cloud-based solutions ahead of Q4 2025 results. For investors focused on catalysts, this updated outlook links directly to the same drivers highlighted in the current earnings expectations, even as questions remain about how far increased diagnostic utilization per visit can offset weaker clinic traffic over time.

Yet behind the optimism around instruments and software, investors should be aware of the risk that sustained weakness in veterinary visit growth could...

IDEXX Laboratories' narrative projects $5.2 billion revenue and $1.3 billion earnings by 2028. This requires 8.8% yearly revenue growth and an earnings increase of about $300 million from $985.7 million today.

Uncover how IDEXX Laboratories' forecasts yield a $754.83 fair value, a 6% upside to its current price.

Exploring Other Perspectives

Five members of the Simply Wall St Community value IDEXX between US$337.49 and US$850 per share, underlining how far opinions can diverge. You can set those varied views against the reliance on Companion Animal Group Diagnostics as a key earnings driver and consider what that might mean for IDEXX if clinic visit trends stay under pressure.

Explore 5 other fair value estimates on IDEXX Laboratories - why the stock might be worth as much as 19% more than the current price!

Build Your Own IDEXX Laboratories Narrative

Disagree with existing narratives? Create your own in under 3 minutes - extraordinary investment returns rarely come from following the herd.

• A great starting point for your IDEXX Laboratories research is our analysis highlighting 2 key rewards and 1 important warning sign that could impact your investment decision.
• Our free IDEXX Laboratories research report provides a comprehensive fundamental analysis summarized in a single visual - the Snowflake - making it easy to evaluate IDEXX Laboratories' overall financial health at a glance.

Contemplating Other Strategies?

These stocks are moving-our analysis flagged them today. Act fast before the price catches up:

• Explore 29 top quantum computing companies leading the revolution in next-gen technology and shaping the future with breakthroughs in quantum algorithms, superconducting qubits, and cutting-edge research.
• The end of cancer? These 29 emerging AI stocks are developing tech that will allow early identification of life changing diseases like cancer and Alzheimer's.
• Find companies with promising cash flow potential yet trading below their fair value.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.